NCT04680052 2025-12-22InMINDIncyte CorporationPhase 3 Active not recruiting654 enrolled 40 charts 1 FDA
NCT04212013 2025-07-23A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaMemorial Sloan Kettering Cancer CenterPhase 3 Active not recruiting23 enrolled